3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
8
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
103
Lung Neoplasms
49
Ovarian Neoplasms
44
Breast Neoplasms
31
Small Cell Lung Carcinoma
25
Neoplasms
20
Fallopian Tube Neoplasms
16
Triple Negative Breast Neoplasms
14
Carcinoma, Ovarian Epithelial
14
Neoplasm Metastasis
12
Adenocarcinoma of Lung
11
Uterine Cervical Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma, Non-Hodgkin
7
Lymphoma
7
Head and Neck Neoplasms
7
Carcinoma
7
Urinary Bladder Neoplasms
6
Esophageal Neoplasms
6
Endometrial Neoplasms
6
Brain Neoplasms
6
Thoracic Neoplasms
5
Prostatic Neoplasms
5
Melanoma
5
Lung Diseases
5
Adenocarcinoma Of Esophagus
5
Adenocarcinoma
5
Respiratory Tract Neoplasms
4
Recurrence
4
Interventions
Gemcitabine
2
rucaparib
1
romidepsin
1
pembrolizumab
1
enfortumab vedotin
1
Trastuzumab
1
Standard of Care
1
Sorafenib
1
Paclitaxel
1
Depsipeptides
1
Crizotinib
1
Cisplatin
1
Carboplatin
1
Afatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Urethral Neoplasms
×
Carboplatin
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA